Published in Kidney Int Suppl on February 23, 2011
Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int (2013) 1.90
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol (2014) 0.99
Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease. Int J Hypertens (2014) 0.97
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol (2012) 0.95
Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate. PLoS One (2013) 0.85
Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks. PLoS One (2011) 0.85
Transplantation of rat embryonic stem cell-derived retinal progenitor cells preserves the retinal structure and function in rat retinal degeneration. Stem Cell Res Ther (2015) 0.83
Critical Parameters of the In Vitro Method of Vascular Smooth Muscle Cell Calcification. PLoS One (2015) 0.75
Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. J Am Heart Assoc (2016) 0.75
Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease. Drugs Context (2016) 0.75
Baroreflex dysfunction in chronic kidney disease. World J Nephrol (2016) 0.75
The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (1998) 10.70
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 5.29
Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res (2006) 3.97
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int (2005) 3.71
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol (2008) 2.65
Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem (1998) 2.10
Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis (2000) 2.05
The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol (2008) 1.99
Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation (2009) 1.85
The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol (2007) 1.81
Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol (2009) 1.67
Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol (2003) 1.67
Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol (2005) 1.54
Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol (2006) 1.37
Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant (2002) 1.27
Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant (1999) 0.92
Vascular smooth muscle cells in the pathogenesis of vascular calcification. Circ Res (2009) 0.88
American Society of Nephrology Presidential Address 2005. J Am Soc Nephrol (2006) 0.78
Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol (2007) 3.74
Bone morphogenetic proteins in vascular calcification. Circ Res (2005) 2.12
The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol (2008) 1.99
Hyperphosphatemia of chronic kidney disease. Kidney Int (2008) 1.63
Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol (2005) 1.54
CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol (2009) 1.40
Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial (2007) 1.24
25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol (2012) 1.01
The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chronic Kidney Dis (2011) 1.00
The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol (2009) 0.96
Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens (2004) 0.91
Microwave-Assisted Synthesis of Titania Nanocubes, Nanospheres and Nanorods for Photocatalytic Dye Degradation. Nanoscale Res Lett (2008) 0.86
Calcium absorption response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol (2013) 0.84
Connections between vascular calcification and progression of chronic kidney disease: therapeutic alternatives. Kidney Int Suppl (2005) 0.83
Poly(methyl methacrylate)-grafted chitosan microspheres for controlled release of ampicillin. J Biomed Mater Res B Appl Biomater (2009) 0.81
Pathophysiology of the chronic kidney disease-mineral bone disorder. Curr Opin Nephrol Hypertens (2015) 0.80
Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol (2009) 0.80
Osteoporosis and cardiovascular disease: lessons from chronic kidney disease. Clin Cases Miner Bone Metab (2008) 0.75
New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Metab (2006) 0.75
Effect of the phosphodiesterase 4 inhibitor, rolipram, on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 cell line. Arch Oral Biol (2003) 0.75